Clinical Trials
- Liver
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
- Ages18 years - 75 years
- GenderBoth
- Liver
A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)
- Ages18 years and older
- GenderBoth
- Liver, Obesity & Weight Management
Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Youth with Obesity
- Ages12 years - 22 years
- GenderBoth
- Children's Health, Liver
The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis
- Ages12 years - 30 years
- GenderBoth
- Diabetes, Blood Disorders, Liver, Immune System
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease